Notice of Capital Markets Update

RNS Number : 9306A

Oncimmune Holdings PLC

27 January 2020

 

Oncimmune Holdings plc

("Oncimmune" or the "Company")

Notice of Capital Markets Update

27 January 2020 - Oncimmune Holdings plc (AIM: ONC.L), a leading global immunodiagnostics group, will be holding a Capital Markets Update for analysts and investors alongside its half year results for the six months ended 30 November 2019, on Wednesday, 12 February 2020.

Adam Hill, Chief Executive Officer and Matthew Hall, Chief Financial Officer, will host a presentation and conference call for analysts at 2:00pm GMT on the day of the results.

To further demonstrate the commercial and clinical  potential of EarlyCDT^® Lung, there will also be presentations by: Kieran O'Kane, Senior Director, Strategic Marketing of Biodesix, Inc.; Katrina Wilson, Principal Advisor to Cancer at Eastern Academic Health Science Network; Javier Sarasqueta, Chief Executive Officer and co-founder of Sabartech S.L.; and Rebecca Allison, lung cancer survivor detected early with EarlyCDT Lung.

To register interest in attending please contact Alex Davis at FTI Consulting at [e-mail] or 020 3727 1000.

-Ends-

For further information:

Oncimmune Holdings plc

Adam Hill, Chief Executive Officer

Matthew Hall, Chief Financial Officer

[e-mail]

Zeus Capital Limited (Nominated Adviser and Joint Broker)

Andrew Jones, Daniel Harris, Victoria Ayton

[phone]

finnCap (Joint Broker)

Geoff Nash, Matthew Radley, Tim Redfern

[phone]

Bryan, Garnier & Co Limited (Joint Broker)

Phil Walker, Dominic Wilson

[phone]

Media enquiries:

FTI Consulting

Ben Atwell, Michael Trace, Alex Davis

[e-mail]

[phone]

About Oncimmune

Beating cancer, one test at a time

The battle against cancer hinges on early detection and then the delivery of effective treatment. Oncimmune is working to revolutionise both the detection of cancer and its treatment by harnessing the sophisticated disease detecting capabilities of the immune system to find cancer in its early stages. Our range of diagnostic tests assist clinicians to identify the presence of cancer four years or more before standard clinical diagnosis, whilst our technology platform and sample biobanks are helping healthcare companies to develop new cancer treatments.

Oncimmune was founded in 2002 and launched its platform technology in 2009, followed by its first commercial tests, EarlyCDT Lung and EarlyCDT Liver. To date, over 158,000 tests have been performed for patients worldwide. EarlyCDT Lung was also used in what is believed to be the largest randomised controlled trial for the early detection of lung cancer using biomarkers, the successful National Health Service (NHS) ECLS trial of 12,209 high-risk smokers in Scotland which demonstrated EarlyCDT Lung reduced the incidence of patients with late-stage lung cancer or unclassified presentation at diagnosis, compared to standard clinical practice.

Oncimmune, headquartered at its laboratory facility in Nottingham, UK, has a discovery research centre in Dortmund, Germany and in London, UK and a partner representative office in Shanghai, China. Oncimmune joined the Alternative Investment Market (AIM) of the London Stock Exchange in May 2016 under the ticker ONC.L.

What is EarlyCDT Lung?

A blood test using a panel of seven immunogenic proteins for the testing of tumour-related antibodies specific to lung cancer.

For more information, visit www.oncimmune.com

 

END

 

 

MSCKKABNOBKDADB